231 related articles for article (PubMed ID: 31985322)
21. Bladder cancer risk stratification using a urinary mRNA biomarker panel - A path towards cystoscopy triaging.
Shkolyar E; Zhao Q; Mach KE; Teslovich NC; Lee TJ; Cox S; Skinner EC; Lu Y; Liao JC
Urol Oncol; 2021 Aug; 39(8):497.e9-497.e15. PubMed ID: 33766467
[TBL] [Abstract][Full Text] [Related]
22. Feasibility study of screening for bladder cancer with urinary molecular markers (the BLU-P project).
Roobol MJ; Bangma CH; el Bouazzaoui S; Franken-Raab CG; Zwarthoff EC
Urol Oncol; 2010; 28(6):686-90. PubMed ID: 21062653
[TBL] [Abstract][Full Text] [Related]
23. Urinary nuclear matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuria.
Miyanaga N; Akaza H; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
Int J Urol; 1999 Apr; 6(4):173-7. PubMed ID: 10226833
[TBL] [Abstract][Full Text] [Related]
24. A urinary assay for mutation and methylation biomarkers in the diagnosis and recurrence prediction of non-muscle invasive bladder cancer patients.
Huang H; Liu A; Liang Y; Xin Y; Liu J; Hao Y; Huang D; Chen L; Li W; Jiang G; Huang Y; Xu Y; Zhang J; Ma T; Xu D; Gao Y
BMC Med; 2023 Sep; 21(1):357. PubMed ID: 37726806
[TBL] [Abstract][Full Text] [Related]
25. Urine cell-based DNA methylation classifier for monitoring bladder cancer.
van der Heijden AG; Mengual L; Ingelmo-Torres M; Lozano JJ; van Rijt-van de Westerlo CCM; Baixauli M; Geavlete B; Moldoveanud C; Ene C; Dinney CP; Czerniak B; Schalken JA; Kiemeney LALM; Ribal MJ; Witjes JA; Alcaraz A
Clin Epigenetics; 2018; 10():71. PubMed ID: 29854012
[TBL] [Abstract][Full Text] [Related]
26. Prospective external validation of a bladder cancer detection model.
Lotan Y; Svatek RS; Krabbe LM; Xylinas E; Klatte T; Shariat SF
J Urol; 2014 Nov; 192(5):1343-8. PubMed ID: 24859442
[TBL] [Abstract][Full Text] [Related]
27. Neural network using combined urine nuclear matrix protein-22, monocyte chemoattractant protein-1 and urinary intercellular adhesion molecule-1 to detect bladder cancer.
Parekattil SJ; Fisher HA; Kogan BA
J Urol; 2003 Mar; 169(3):917-20. PubMed ID: 12576812
[TBL] [Abstract][Full Text] [Related]
28. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer.
Zippe C; Pandrangi L; Potts JM; Kursh E; Novick A; Agarwal A
Anticancer Res; 1999; 19(4A):2621-3. PubMed ID: 10470205
[TBL] [Abstract][Full Text] [Related]
29. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.
Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ
Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893
[TBL] [Abstract][Full Text] [Related]
30. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria.
O'Sullivan P; Sharples K; Dalphin M; Davidson P; Gilling P; Cambridge L; Harvey J; Toro T; Giles N; Luxmanan C; Alves CF; Yoon HS; Hinder V; Masters J; Kennedy-Smith A; Beaven T; Guilford PJ
J Urol; 2012 Sep; 188(3):741-7. PubMed ID: 22818138
[TBL] [Abstract][Full Text] [Related]
31. Immunocytology is a strong predictor of bladder cancer presence in patients with painless hematuria: a multicentre study.
Cha EK; Tirsar LA; Schwentner C; Christos PJ; Mian C; Hennenlotter J; Martini T; Stenzl A; Pycha A; Shariat SF; Schmitz-Dräger BJ
Eur Urol; 2012 Jan; 61(1):185-92. PubMed ID: 21924544
[TBL] [Abstract][Full Text] [Related]
32. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria.
Sarosdy MF; Kahn PR; Ziffer MD; Love WR; Barkin J; Abara EO; Jansz K; Bridge JA; Johansson SL; Persons DL; Gibson JS
J Urol; 2006 Jul; 176(1):44-7. PubMed ID: 16753364
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic predictive value of the Bladder EpiCheck test in the follow-up of patients with non-muscle-invasive bladder cancer.
Trenti E; D'Elia C; Mian C; Schwienbacher C; Hanspeter E; Pycha A; Kafka M; Degener S; Danuser H; Roth S; Pycha A
Cancer Cytopathol; 2019 Jul; 127(7):465-469. PubMed ID: 31154670
[TBL] [Abstract][Full Text] [Related]
34. Utility of urine cytology in the workup of asymptomatic microscopic hematuria in low-risk patients.
Feifer AH; Steinberg J; Tanguay S; Aprikian AG; Brimo F; Kassouf W
Urology; 2010 Jun; 75(6):1278-82. PubMed ID: 20138655
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic tests in urology: urine cytology.
Lavallée LT; Fergusson D; Dahm P; Scales CD; Witiuk K; Breau RH
BJU Int; 2012 Dec; 110(11 Pt C):E789-91. PubMed ID: 23106855
[TBL] [Abstract][Full Text] [Related]
36. [Gross hematuria and usefulness of urinary cytology: Experience at hematuria one stop clinic.].
Sánchez Verdes P; Fernández-Pello S; González Rodríguez I; Salgado Plonski JJ; Alonso Calvar L; Suárez Sal PJ; Rodríguez Villamil L
Arch Esp Urol; 2021 Jun; 74(5):470-476. PubMed ID: 34080566
[TBL] [Abstract][Full Text] [Related]
37. Filtration Device for On-Site Collection, Storage and Shipment of Cells from Urine and Its Application to DNA-Based Detection of Bladder Cancer.
Andersson E; Dahmcke CM; Steven K; Larsen LK; Guldberg P
PLoS One; 2015; 10(7):e0131889. PubMed ID: 26151138
[TBL] [Abstract][Full Text] [Related]
38. FGFR3 mutation analysis in voided urine samples to decrease cystoscopies and cost in nonmuscle invasive bladder cancer surveillance: a comparison of 3 strategies.
van Kessel KE; Kompier LC; de Bekker-Grob EW; Zuiverloon TC; Vergouwe Y; Zwarthoff EC; Steyerberg EW
J Urol; 2013 May; 189(5):1676-81. PubMed ID: 23142690
[TBL] [Abstract][Full Text] [Related]
39. Carbonic anhydrase IX as a diagnostic urinary marker for urothelial bladder cancer.
de Martino M; Lucca I; Mbeutcha A; Wiener HG; Haitel A; Susani M; Shariat SF; Klatte T
Eur Urol; 2015 Oct; 68(4):552-4. PubMed ID: 26138037
[TBL] [Abstract][Full Text] [Related]
40. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer.
Sánchez-Carbayo M; Urrutia M; Silva JM; Romaní R; De Buitrago JM; Navajo JA
J Urol; 2001 May; 165(5):1462-7. PubMed ID: 11342897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]